A rapid and simple LC-MS/MS method for the simultaneous evaluation of CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 hydroxylation capacity

被引：28

作者：

de Andres, Fernando ^{[1
]}

Sosa-Macias, Martha ^{[2
]}

LLerena, Adrian ^{[1
]}

机构：

[1] Univ Extremadura, Hosp & Med Sch, CICAB Clin Res Ctr, E-06071 Badajoz, Spain

[2] CIIDIR IPN, Ctr Interdisciplinario Invest El Desarrallo Integ, Durango 34220, Mexico

来源：

BIOANALYSIS | 2014年 / 6卷 / 05期

关键词：

TANDEM MASS-SPECTROMETRY; IN-VIVO; DRUG-METABOLISM; PROBE DRUGS; HUMAN PLASMA; CYTOCHROME-P450; COCKTAIL; DEXTROMETHORPHAN; CAFFEINE; PHARMACOKINETICS;

D O I：

10.4155/bio.14.20

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

Background: The analytical method here reported for the CEIBA cocktail approach has been developed and validated for the simultaneous determination of several probe drugs and their corresponding cytochrome P450 (CYP) enzyme-specific metabolites in just one analysis. This methodology has been proposed in order to overcome some drawbacks concerning the complexity and low throughput of analytical methodologies associated with previously proposed cocktail approaches. Methods & results: Caffeine (CYP1A2), losartan (CYP2C9), omeprazole (CYP2C19), dextromethorphan (CYP2D6 and CYP3A4) and their corresponding metabolites were all analyzed in a single analytical run by gradient LC coupled to MS/MS. Sample preparation was conducted with solid-phase extraction. This method was fully validated and applied to CYP450 enzyme phenotyping of 20 healthy volunteers. Conclusion: This method constitutes a rapid and simplified analytical tool to be used with the CEIBA cocktail approach for the main CYP450 enzymes phenotyping.

引用

页码：683 / 696

页数：14

共 38 条

[1] Quantitative characterization of differential ion suppression on liquid chromatography/atmospheric pressure ionization mass spectrometric bioanalytical methods [J].

Avery, MJ .

RAPID COMMUNICATIONS IN MASS SPECTROMETRY, 2003, 17 (03) :197-201

[2] CYP2C9 genetic variants and losartan oxidation in a Turkish population [J].

Babaoglu, MO ;

Yasar, U ;

Sandberg, M ;

Eliasson, E ;

Dahl, ML ;

Kayaalp, SO ;

Bozkurt, A .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 60 (05) :337-342

[3] Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions [J].

Bertz, RJ ;

Granneman, GR .

CLINICAL PHARMACOKINETICS, 1997, 32 (03) :210-258

[4] A COCKTAIL STRATEGY TO ASSESS INVIVO OXIDATIVE DRUG-METABOLISM IN HUMANS [J].

BREIMER, DD ;

SCHELLENS, JHM .

TRENDS IN PHARMACOLOGICAL SCIENCES, 1990, 11 (06) :223-225

[5] The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans [J].

Capon, DA ;

Bochner, F ;

Kerry, N ;

Mikus, G ;

Danz, C ;

Somogyi, AA .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 60 (03) :295-307

[6] Intra-individual variability and influence of urine collection period on dextromethorphan metabolic ratios in healthy subjects [J].

Chládek, J ;

Zimová, G ;

Martínková, J ;

Tuma, I .

FUNDAMENTAL & CLINICAL PHARMACOLOGY, 1999, 13 (04) :508-515

[7]

Committee for Medicinal Products for Human Use European Medicines Agency, 2011, GUID BIOAN METH VAL

[8]

de Andres Fernando, 2013, Drug Metabolism and Drug Interactions, V28, P135, DOI 10.1515/dmdi-2013-0020

[9] Pharmacokinetic drug interaction potential of risperidone with cytochrome P450 isozymes as assessed by the dextromethorphan, the caffeine, and the mephenytoin test [J].

Eap, CB ;

Bondolfi, G ;

Zullino, D ;

Bryois, C ;

Fuciec, M ;

Savary, L ;

Jonzier-Perey, M ;

Baumann, P .

THERAPEUTIC DRUG MONITORING, 2001, 23 (03) :228-231

[10]

Eichhorst Jeff C, 2012, Methods Mol Biol, V902, P29, DOI 10.1007/978-1-61779-934-1_3

← 1 2 3 4 →